JOURNAL OF APPLIED BIOANALYSIS, June. 2024, p. 96-113.
https://doi.org/10.53555/jab.v10.006 (ISSN 2405-710X)
Vol. 10, No. 1

OPEN ACCESS

Exploring New Avenues In Drug Discovery And Development: Insight Into Pharmacokinetics And Pharmacodynamics

Dr. Itishree Prusty[1*], Dr. Sailen Kumar Mishra[2], Saswat Satapathy[3], Dr. Yajnesh Prasanna Sahu[4], Harmohan Singh Yadav[5], Dr. Dinesh Kumar Mishra[6]

[1]Assistant Professor, Department of Pharmacology, SCB Medical College, Cuttack, India. Email: iprusty345@gmail.com*
[2]Assistant Professor Pharmacology, Shri Jagannath Medical College & Hospital, Puri, Odisha, India. Email: sailenmbbs@gmail.com
[3]Assistant Professor, Department of Pharmacology, Saheed Rendo Majhi Medical College, Kalahandi, India. Email: saswat.satapathy140492@gmail.com
[4]Assistant Professor, Department of Pharmacology, Bhima Bhoi Medical College, Balangir, Odisha, India. Email: drypsahu@gmail.com
[5]Associate Professor, Department of Biochemistry, Rama Medical College Hospital & Research Centre, Mandhana, Kanpur (U.P) - 209 217. India. Email: sukantoaxum@gmail.com
[6]Associate Professor, Department of Chemistry, AKS University Satna, Madhya Pradesh, India. Email: mishra.dinesh2@gmail.com
[7]Association Professor, Department of soil science and agricultural chemistry, School of Agriculture, Lovely Professional University, Jalandhar, Punjab, India. 144411. Email: drhms.srcm@gmail.com

The field of drug discovery and development is constantly evolving due to advancements in pharmacokinetics and pharmacodynamics research. The abstract explores the latest insights and methodologies influencing the critical aspects of drug development. Pharmacokinetics, which includes absorption, distribution, metabolism, and excretion (ADME), is crucial for evaluating the safety and efficacy of medications. Nanotechnology and targeted drug delivery are revolutionizing the interaction between drugs and biological systems. Pharmacodynamics studies integrate drugs and molecular targets to understand their interactions, revealing efficacy, potency, and potential adverse effects. The article discusses recent advancements in comprehending drug-receptor interactions, signaling pathways, and therapeutic response variability. Emerging technologies like computational modeling and high-throughput screening are accelerating the discovery of new drug candidates. This explores new drug discovery and development avenues, contributing to ongoing dialogue on optimizing therapeutic interventions and translating basic research into clinical applications. With an emphasis on the complex mechanisms regulating therapeutic efficacy and safety, this abstract examines the significance of pharmacokinetics and pharmacodynamics in drug discovery and development. It highlights recent advancements in drug delivery systems, such as nanoparticle-based platforms, and the use of cutting-edge methodologies like computational modeling and high-throughput screening. The aim is to develop safer, more effective therapeutics and advance personalized medicine.

Keywords: Drug discovery, Pharmacokinetics, Pharmacodynamics, Target, drug delivery systems, biological systems

1. Introduction

The free drug hypothesis suggests unbound drug concentrations have greater pharmacological significance, but preclinical settings often associate plasma or tissue drug concentrations with pharmacodynamics. As an alternative, blood concentrations for passively permeable substances might serve as a reliable proxy for tissue concentration. Many substances that act as substrates for uptake and efflux transporters at the tissue level are expected to have varying unbound

***Corresponding author**: Dr. Itishree Prusty
*Email: iprusty345@gmail.com

quantities in blood and tissue. Mariyappan et al. (2013) pharmacokinetics and pharmacodynamics (PK/PD) studies are crucial in drug research and development, conducted by experts in the pharmaceutical industry, focusing on the pharmacodynamic component within specific disease areas, while DMPK laboratories measure concentrations and assess pharmacokinetics. The animals utilized in the PD study are not always used to evaluate pharmacokinetics. Instead, it's possible that the PK and PD databases were produced entirely separately from one another, possibly even in other facilities and at different times. In the latter case, data creation and reporting may occur independently, leaving project teams to combine and evaluate the information downstream without doing a comprehensive analysis that defines a concentration-effect link. When designing and carrying out PK/PD research, it is ideal for DMPK and pharmacology professionals to carry out the PK/PD analysis, conclusions, and interpretations, with assistance from other pertinent partners. As a result, the final report incorporates all pertinent information and answers the initial hypothesis or query of the research. The report will discuss assumptions, future research, and the shared responsibility of pharmacology and DMPK experts in early drug development, focusing on selecting promising compounds and establishing safe doses. Early PK/PD integration aids in compound selection and directs the formulation of a successful clinical development plan. Miller et al. (2013), Tuntland et al. (2014), common uses of these techniques include evaluating exposure-response correlations, estimating safety and efficacy, measuring drug disposition and pharmacological effects, and using pharmacokinetic/ pharmacodynamic and computer-aided methods. The efficient use of modeling and simulation in drug development can significantly enhance the design and interpretation of preclinical and clinical studies. When there is a solid biological understanding, mechanism-based methods are used to help science-based decision-making by offering relevant quantitative comparisons between alternatives. These models' simulations enable researchers to explore a range of trial designs with explicit assumptions. This article reviews commercially available PK/PD software tools and their potential use in drug research and development, highlighting their potential to expedite the development of new treatments. Dong et al. (2008) creating the best possible drug regimens to treat diseases requires an understanding of how drugs behave throughout the pediatric age range. Drug distribution and effect are influenced by various factors, including organ function, body composition, endogenous functions, genetics, and disease. Even with the advancements in pharmacometric analysis and technology, pinpointing the precise effects of age and illness on drug disposition is still difficult to do. More understanding will help with medication disposition-effect modeling, enhance clinical trials, and enable more efficient assessment of novel pharmacologic agents for pediatric patients. Van Den Anker et al. (2018), drug research involves forecasting human pharmacokinetics and disposition attributes of novel drugs, optimizing compound design using human-derived reagents and in vitro approaches to reduce attrition rates. Clearance, distribution volume, half-life, absorption, and drug-drug interactions are among the predictions. Di L et al. (2013), the process of discovering new drugs, focusing on (PK/PD) interactions and animal pain models, with PD measuring drug interactions and PK examining body effects. The chapter discusses the definition of structure-activity relationship (SAR) in vivo and in vitro, emphasizing the importance of integrating side effects and efficacy models. Whiteside et al. (2011), modeling and simulation aid in early risk assessment and cost reduction in drug development, particularly in oncology, providing a comprehensive understanding from discovery to lifecycle management. Block, (2015), due to halted medication development and increased resistance, pharmacokinetic and pharmacodynamic studies are crucial for maintaining and optimizing current medications on the market. Pharmacokinetics studies drug absorption, distribution, metabolism, and excretion, while PD investigates the relationship between drug concentrations and their effects at action sites. The only pharmacologic compounds that operate on another living organism are antimicrobials, making them special. To maximize an agent's efficacy and minimize its toxicity, which will eventually enhance patient outcomes and extend the drug's shelf life, The link between dose, exposure, and response must be established. PK and PD integration can be used to accomplish this. Dhrusano (2004) rigid PK/PD approaches and dose optimization have transformed antibacterial development, reducing costs, maximizing efficacy, preventing resistance, lowering toxicity, and minimizing clinical study failures. Bhavani et al. (2020) explore the role of PK and PD in drug discovery and development. It highlights the importance of understanding the relationship between drug exposure and response for predicting and optimizing therapeutic outcomes. The study also highlights the integration of quantitative PK/PD approaches with emerging technologies like microdosing and in silico modeling. Translational PK/PD research helps bridge the gap between preclinical findings and clinical outcomes, optimizing drug dosing strategies and predicting human pharmacokinetics.

2. Recognize target biology

Understanding the target biology and mechanism(s) of action is crucial for developing a medicine, which can be challenging, time-consuming, and complex initially. Gabbrielson et al. (2018) different deconvolution methods may be necessary for drug exploration and development attempts, although this is still a possibility. Terstappen et al. (2007), Tardiff et al. (2013) small molecule drug discovery typically begins with screening chemical libraries against single targets, but in vivo studies are crucial for evaluating chosen agents' drug action in larger organisms. Understanding a target's location, function, and situational impact in both normal and pathological physiological situations will make it easier to identify connections between drug exposure and effect. Pharmacological response-time data can aid in drug ranking, research design, safety evaluation, and initial human dose estimates, despite limited biological knowledge. Gabbrielson et al. (2016) and a minimal number of assumptions, and plausible mechanistic theories can be developed about how a medicine might modify a crucial component to cause the response readout. Six data patterns illustrating scenarios where target biology is poorly understood, including irreversible enzyme binding, cell death, motility, reversible inhibition of response biomarker formation, and EEG response (Gabbrielson et al. 2016; Gabbrielson et al., 2001; Drexler et al., 2018). In instances (i) through (iii), we begin with the baseline biology knowledge and "drive" the model-building process using the specified target mechanism. In contrast, the actual observed data is used in cases (iv)–(vi) to help us create equations that closely resemble the time–response data. It could also be beneficial to mention a few more points here: In Case Example (iii) a medication that forms an irreversible bond with the enzyme is used to suppress the biomarker response and quicken the process of loss. In contrast, the basal natural turnover in this instance—specifically, the enzyme's rate of regeneration—controls the response's ability to recover. It is also simpler to generate predictions outside of the data domain if the model is built around the mechanism of action. For the aim of interpolating between doses and determining pharmacologically effective concentrations, a strictly mathematical interpretation of the data is appropriate, although it is not necessarily helpful in advancing biological understanding of the background target processes. A unique circumstance arises when behavioral readouts are obtained from an intact animal during pharmacological testing. Any such model that is employed must be extremely cautious while controlling for any data confounders. Rats' locomotor activity is the response readout in Case Example (iv) following two intraperitoneal amphetamine dosages Van Rossum et al (1968). The reported hyperactivity is likely due to a well-known drug that is an indirect CNS dopamine (DA) stimulant. Amphetamine's mechanism likely involves various DA transmission-promoting events, including direct and indirect ones, with importance varying depending on dosage. Calipari et al. (2013) nondrug motor activity baseline levels depend on surroundings and light-dark cycle changes, while excessive use of dopaminergic stimulants can lead to behavioral stereotypies. The baseline nondrug motor activity is influenced by the environment and familiarity with the factor, which fluctuates with the light-dark cycle. Excessive dopaminergic stimulants can cause behavioral stereotypes (Gabbrielsom et al., 2014).

3. Predicting in vivo clearance using data from in vitro metabolism

Clearance (CL) is a crucial PK metric that measures the volume of bodily fluid, like plasma, that a drug excretes or eliminates through biotransformation. Human clinical learning is a crucial tool in drug discovery, as it determines the exposure and fate of a medication in the body. High-throughput evaluation of in vitro metabolic stability and metabolism, typically using liver preparation from preclinical species and humans, enhances understanding of structure-activity correlations for metabolic liability. Some suggest that in vivo CL assessment can be achieved by utilizing in vitro metabolism tests to determine intrinsic CL (Obach et al., 1997; Ito et al., 2004; Azad et al., 2024). The accuracy and reliability of using metabolic stability data to predict in vivo CL are being questioned by Iwatsubo et al. (1997), Anderson et al. (2004). We have explored the relationship between CLs in vivo and in vitro for various structurally different drugs. Hepatocytes, mice hepatic microsomes, and the S9 fraction were utilized for in vitro intrinsic CL generation due to their metabolic stability. Next, a comparison was made between the estimated hepatic clearance and the mouse's actual in vivo CL. The in vivo CL prediction and observation agreement for drugs was only satisfactory for 45%, and the correlation did not improve with microsome binding or plasma protein addition. Tissue uptake, physicochemical properties, extrahepatic clearance, and transporter-mediated CL are a few possible causes of this discrepancy. Recent data indicates that in vivo CL increases with increasing polar surface area for structurally similar compounds, Sarawek et al. (2009). found that 20% of medicines understudied had their in vivo CL underestimated by conventional in vitro metabolism experiments, The intravenous injection of these drugs, which were not anticipated, was significantly increased due to hepatic

transporter-mediated absorption (Soars et al., 2009). The paper introduces a novel method for predicting an individual's in vivo drug metabolism using in vitro data from human liver microsomes or hepatocytes. Successful predictions were made for certain compounds, but differences were observed for others due to factors like metabolism in other tissues, incorrect drug equilibrium assumptions, active transport, and interindividual variability. Additionally, a human P450 isozyme recombinant system was utilized to forecast clearance for a model drug, YM796, even in nonlinear first-pass metabolism (Iwatsubo et al., 1997). The r2 values of in vitro methods like artificial neural networks and physiologically based direct scaling are less than 0.44 when combined with in vivo preclinical data. Rat allometric scaling produced a prediction success rate of 55%, whereas the other techniques produced a percentage of between 64 and 68% of correct predictions (less than a 2-fold error). These investigations demonstrated that the most accurate and economical methods, methods that are exclusively dependent on in vitro data, direct scaling with a physiological foundation and empirical in vitro-in vivo correlation, using a wide range of 22 metabolized drug compounds. Predictive accuracy was not considerably increased by adding in vivo preclinical data; in fact, the allometric approaches' prediction accuracy was the lowest of all the techniques examined (Zuegge et al., 2001). Cryopreserved human hepatocytes can predict in vivo metabolic clearance, but underestimation has been noted. A scaling factor based on regression reduces disparity. The study explores the underprediction of hepatocytes' intrinsic clearance and its mechanisms, highlighting the importance of hepatic uptake clearance in accurate forecasting (Chiba et al., 2009). This article explores strategies to improve in vitro data on CYP inhibition and metabolic stability to predict in vivo outcomes. It highlights potential pitfalls and inaccuracies and recommends best practices. This text discusses the use of hepatic microsomes and isolated hepatocytes for evaluating metabolic stability, highlighting the importance of combining data with medication pharmacokinetics (Houston et al., 2008).

4. Using the microdose approach in the early stages of drug development

Recently, the concept of Phase 0 or microdose research has been introduced to expedite the clinical PK of a new molecular entity (Kumar et al., 2007). Microdose studies compare traditional Phase Ia PK investigations to a subtherapeutic dose, with a maximum dose of ≤100 μg (Lorusso et al., 2009; Gaugler et al., 2018). Clinical microdose research can be started with fewer preclinical studies because of the low dosage. One possible benefit of this is that it could speed up the process of getting human PK data (Marchetti et al., 2007). Microdosing is used in early clinical candidate selection when preclinical evidence is inconclusive, but it's crucial to acknowledge its limitations. The ability to considerably reduce the time required for final regulatory approval, for example, has not yet been proven. One possible drawback of the chemical is its potentially non-linear pharmacokinetic profile from a microdose to a therapeutic dose (Yu et al., 2010). Exploratory clinical trials are preliminary human studies that assess subtherapeutic dosages of new drugs using phase 0 techniques like microdosing. Recent developments expand the benefits of phase 0 beyond pharmacokinetic assessment to encompass pharmacodynamics and mechanism of action comprehension. Phase 0 techniques can facilitate safer, more affordable, quicker, and better-informed developmental decisions and enhance preclinical candidate selection. Here, it addresses extrapolation and developmental timescale problems, go into phase 0 methodologies and applications, and emphasizes their benefits over conventional approaches. Despite ongoing challenges, it is recommended to consider phase 0 approaches for deployment in most drug development scenarios (Burt et al., 2020). Microdosing is an early drug development approach that uses safe sub-pharmacologic doses of drugs to acquire exploratory pharmacokinetic data in humans. Experts suggest micro-dosing as a more effective predictive tool for drug-drug interactions, polymorphism, and monitoring drug concentrations over time, potentially resulting in more accurate future predictions (Lappin et al., 2013). It's still not widely accepted that microdose pharmacokinetic studies are a crucial tool in medication development. Although there is a chance that this method may save a lot of money and improve the efficiency of the drug development process, there are still significant obstacles that must be cleared before the methodology is widely used. In the USA and Europe, clear regulations have made things easier. Despite the minimal risk and obvious importance for the domestic drug development business, India's regulatory framework does not support microdosing trials, which is incongruent with the nation's goal of becoming a global leader in pharmaceutical research. A human microdosing study involves selecting compounds, determining therapeutic doses using animal PK data and scaling methodology, conducting a 14-day single-dose toxicity study, submitting a microdosing CTA or exploratory IND, obtaining 14C-labeled drug if necessary, standardizing and validating dosing and bioanalytical methods, designing the study, and analyzing samples. Bioanalysis in microdosing studies is challenging due to the sensitivity required for detecting small

quantities of drugs in circulation. Accelerated Mass Spectrometry (AMS) is used for high distribution or low bioavailability medication series, but cannot distinguish parent medications and metabolites, requiring a subsequent HPLC step. Radiolabeling facilitates scintigraphy, but high equipment and drug labeling costs, vendor oligopoly, radiation exposure rules, and radiopharmaceutical regulations can hinder its use. Because of the increased sensitivity of LC/MS/MS, pharmacological microdose investigations employing traditional analytical methods are now possible. Filters are not necessary for measuring accurate parent drug levels, eliminating radiolabeling-related complications. Incremental costs are low, but method optimization may be required. Disadvantages include non-specific drug binding and metabolism studies requiring key metabolite analysis. The US FDA permits repeated dosages of microdosing for up to seven days, unlike the European Union's IV route, allowing for more creative uses (Tewari et al., 2010).

5. Classification of PK/PD model

PK/PD models are either empirical or mechanistic models according to model development principles. Empirical models disregard the underlying mechanical foundations in favor of phenomenological correlations between exposure and effect (Sheiner et al., 2020). Numerous empirical models are available, such as circadian models, logistic regression models, spline-function models, and direct-link models (Uchizono et al., 2007). Circadian models have been utilized to study daily fluctuations in various bodily functions such as blood pressure, temperature, white blood cell count, serum glucose, QTc interval, and hormone concentrations (Dokoumetzidis et al., 2002, Rohatagi et al., 2009). Empirical models are crucial in understanding the pathophysiology of human diseases like tumor growth and Alzheimer's syndrome, as their development is often poorly understood (Yamasaki et al., 1984, Ashford et al., 2001). The tumors in xenograft tumor models initially grow exponentially, then linearly. (Simeoni et al., 2004) A fresh empirical model in which the tumor's size acts as a trigger to change the tumor's growth from its initial exponential phase to a linear phase. All things considered, empirical models continue to be a helpful and realistic strategy in the present paradigm of drug development. On the other hand, the mechanistic approach is grounded in physiology. Mechanistic model creation typically depends on biomarker response data that is relevant to pharmacology and/or clinical settings. Compared to empirical models, mechanistic models might offer a more accurate prediction across species, populations, and dosage schedules (Dahnnof et al., 2007). Drug research and discovery are increasingly using mechanistic models. Animal research aids clinical translation, drug discovery, and PK/PD models. THI inhibits S1P lyase, decreasing peripheral lymphocytes and increasing lymphoid S1P levels. Our mechanistically based model, consisting of three sub-models, explains that THI inhibits S1P lyase, potentially reducing peripheral lymphocyte quantity in rats, which would raise splenic S1P levels (Yu et al., 2010; Faria et al., 2020). The PD response at various dose levels could be predicted using this PK-biomarker-PD model (Yu et al., 2010). Beier et al. successfully utilized a semi-mechanistic model, including an indirect-II PD model and a competitive interaction model, to study the antinociceptive effects in rats (Beier et al., 2008). PK/PD modeling, a mechanistic science covering the entire drug development life cycle, provides precise causal relationships between drug administration and effect, outperforming empirical descriptive models. This paper proposes a unique biomarker classification scheme for mechanism-based PK/PD modeling, focusing on accurately characterizing the causal chain between drug administration and effect. This work presents a novel biomarker categorization approach, utilizing seven categories including drug response genotype/phenotype, drug concentration, molecular target occupancy/activation, physiological measure, pathophysiological in Fig.1 measure, and clinical rating (Danhof et al., 2005). PK-PD modeling enhances medication safety and efficacy in translational drug development by forecasting safety and efficacy in humans based on in vitro bioassays and in vivo animal research. PK-PD models, based on mechanisms, provide precise descriptions of the sequence of events from drug exposure to drug response. PK-PD models describe target-site distribution, binding, activation, and transduction, revealing how drug effect interacts with disease processes and course. This gives instances of modern uses for PK-PD modeling based on mechanisms (Danhof et al., 2008).



Fig. 1. Pathophysiological conditions, pharmacokinetics, and pharmacodynamics that influence a drug's clinical result. The figure depicts various pharmacokinetic and pharmacodynamic processes involved in drug transformation and clinical effects. It details pathophysiological conditions that may impact either PK or PD

6. Start and Modify a PK/PD Model

A useful method for combining quantitative data on a compound's pharmacologic characteristics with its pharmacokinetics is PK/PD modeling. A reasonable research design is predicated on the notion that a drug's therapeutic action and exposure have a causal link. These kinds of connections are typically intricate. For this reason, it's critical to plan solid preclinical research that will yield data for the creation of mathematical models of PK/PD that are mechanistically relevant. Iteratively improving initial models is possible as more data becomes available. The final result is a potent forecasting instrument founded on a comprehensive comprehension of the prerequisites for effectiveness. PK/PD studies that are carefully considered offer a rationale for efficient and instructive medication development. The development process utilizes PK/PD modeling to predict drug dose ranges, estimate therapeutic index, expedite development, and reduce animal use in early clinical trials. Based on our understanding of drugs and diseases, PK/PD models enable the logical integration of data from many investigations. One way to think about drug discovery and development is as a model-building process where novel compounds are constantly being discovered and utilized to guide strategy and decision-making (Lalonde et al., 2007; Alampanos et al., 2019). An "applied science" approach that can be used to more rapidly and cheaply provide answers about the safety and effectiveness of innovative medications is PK/PD modeling and

simulation. PK/PD models can be used in drug development at every stage, from preclinical to clinical. Fewer unsuccessful drugs, fewer unsuccessful studies, and fewer studies required for registration will result from the best possible application of PK/PD modeling and simulation. PK/PD modeling is necessary for it to reach its full potential in drug development (Rajman, 2008).

7. Study design of PK/PD

Standard protocols for designing PK/PD studies involve collecting in vivo and in vitro pharmacokinetic data, and then using an acute pilot model to examine the relationship between exposure and response. Acute disease models are limited and short-term, focusing on single biomarkers and dosages. Drug discovery involves an iterative process of setting up and screening PK/PD models, constantly updating with new data. Sub-chronic major PK/PD studies are conducted to determine effective plasma target concentration ranges and dose-exposure-response relationships after discovering suitable drug candidates. Sub-chronic disease models identify effective concentrations of substances, while comprehensive chronic illness models determine the lowest effective dose and the relationship between sustained efficacy and steady-

state exposure (Gabbrielson et al., 2009). Future work will build models of chronic diseases, which are often complicated and long-lasting, to properly characterize the exposure-response relationship. These models could involve numerous biomarker monitoring, frequent blood and target tissue collection, and daily dosing for two weeks at various dose levels. The materials selected in earlier screenings utilizing a variety of in vitro assays receive feedback or confirmation from the outcomes of the sickness models and mechanistic biomarker screens. Before starting a PK/PD examination, it is crucial to set objectives and identify any gaps in the study's data as well as its strengths and shortcomings. Teams should consider PK in test animal species, vivo and in vitro efficacy, PD read-out, and time-related effects, with thorough planning incorporating feedback from pharmacology, DMPK, and team members. Scientists must agree on protocol details, including administration, study duration, and sample frequency, while experimental design is guided by PK and effectiveness data, using various methodologies based on the project stage. PK/PD modeling is crucial for early proof of concept investigations, acute illness screening, sub-chronic efficacy models, and later-stage chronic disease models to accurately characterize exposure-response relationships and assess biotherapeutic drugs (Agoram et al., 2007; Yu et al., 2009; Jumbe et al., 2009; Gao et al., 2012). Large molecules' PK and PD vary from small molecules in several ways. For example, in a process known as target-mediated drug disposition (TMDD), the PK may be dependent on PD (Gibiansky et al., 2009). For therapeutic applications to be applied effectively, it is critical to comprehend the parameters that influence the PK of antibodies (Tabrizi et al., 2006). On the subject of PK/PD modeling of antibody and protein therapies, several outstanding review articles and books have been published (Lobo et al., 2004, Wang et al., 2008, Meibohm et al., 2004, Praveen and Morales-Bayuelo, 2023). The study conducted a quantitative pharmacodynamic study on the impact of sildenafil on pregabalin pharmacokinetics in rats, assessing the effects of different intravenous infusion doses. Pregabalin pharmacokinetics were described using a two-compartment population PK model, with three post-PD samples achieving the best cost/benefit ratio, enhancing bias and precision in PK and PD parameters (Bender et al., 2009).

8. Biomarkers of disease and medication effects

The causal link between medication administration and human effects is crucial for predicting pharmaceutical effects using mathematical and translational animal models, including target site distribution, binding, and transmission. Ultimately, consideration must be given to the effects on disease processes and progression. The biomarker classification in Table 1. scheme states biomarkers can be used to characterize these. Better, more accurate, and more predictable models can be developed with the combination of data on several biomarker types, ideally in tandem inside a single biological system. The more effective preclinical models we can create, the fewer, frequently very expensive clinical trials we will need to do. Therefore, the main emphasis should be on designing quantitative in vivo animal investigations that allow for the application of translational pharmacology techniques (Friden et al., 2009; de Lange, 2013; de Lange, 2015; Boxeman, 1998), Multimodal neuroimaging, including PET/SPECT, provides data on morphology, function, biochemistry, and metabolism for TO assessment, aiding in refined animal models. Modifying drug PK, TO, and biomarker profiles is increasingly used to assess pathophysiological alterations in disease states, including BBB integrity, target expression, cerebral blood flow, neurotransmitter release, and neuroinflammation/glial activation (Finnema et al., 2015; Liu et al., 2015; Slifstein et al., 2017). The study of biological system functioning and the benefits of a multi-biomarker approach in disease states and medication delivery is expanding (Kaddurah-Daouk et al., 2008; Greef et al., 2005). A multi-biomarker response then reflects the system-wide pathogenic and pharmacological impacts. Therefore, it's critical to link these data to knowledge on target binding kinetics, signal transduction, drug distribution to target sites, and homeostatic feedback mechanisms. By integrating data from multilevel studies—that is, measuring various biomarker types in a time-dependent manner—such knowledge can be gained (Brink et al., 2017; Lange et al., 2005; Morgan et al., 2012; Groenveld et al., 2016; Praveen, 2024). Drug R productivity is declining in clinical-stage testing, especially for chronic diseases. Integrative analytics in Systems Biology combines reductionist and exploratory methodologies to explain treatment response and outcome by bridging the gap between clinical phenotypic surrogates and molecular disease characteristics. Adaptive clinical trials using biomarker-based enrichment algorithms offer ways to address development attrition and improve the accuracy of medication development and clinical procedures (Mayer et al., 2017). The 21st Century Cures Act in 2016 boosted the Precision Medicine Initiative, promoting molecular medicine and increasing clinical trial efficiency by formalizing the FDA's qualifying procedure for drug development tools. FDA and EMA develop similar processes for medication development, regulatory approval, and biomarker qualification, with FDA not requiring approval for biomarkers used for patient diagnosis or clinical trials. This document covers the

development, benefits, drawbacks, identification, analytical validation, clinical qualification, and application of biomarkers (Kraus, 2018; Praveen, 2024). Biomarkers provide a powerful and dynamic means of understanding the range of diseases, with applications in randomized clinical trials, screening, diagnosis, and prognosis, as well as observational and analytical epidemiology. Markers, based on changes in tissue or fluid components, accurately classify diseases and risk factors, enhancing our understanding of disease pathophysiology. Clarification of the precise indication, standardization of analytical techniques, characterization of analytical features, and incremental yield of various markers for specific clinical indications are requirements for the clinical application of biomarkers. Biomarkers are crucial in medical research as they can accurately track the entire course of a disease, from its initial signs to its final phases (Sahu et al., 2011).

Table 1. Classification of biomarkers and methods for evaluating quantitative data.

Biomarker	*Description*	*Approaches*	*Ref.*
Type 0	Genotype or phenotype	Genotype and phenotype are key factors in drug response, influencing target site exposure and response due to variations in enzyme or receptor expression. Gene expression data has significantly influenced research on BBB development, function, and dysfunction, with genome-wide microarray expression sets now available. The study explores changes in disease conditions using quantitative targeted absolute proteomics and quantitative targeted metabolomics to obtain information on protein expression levels and enzyme conversion rates.	Uchida et al. (2013) Uchida et al. (2015) Huntley et al. (2014) Bergen et al. (2015) Flaker et al. (2017)
Type 1	Drug concentrations overall and specifically at the targeted location.	Quantitative biomarkers for drug and metabolite target site distribution in the CNS are challenging to obtain in humans but readily available in animals in vivo.	Sawada et al. (1991) Wang et al. (1996) Westerhout et al. (2012) Westerhout et al. (2014) Yamamoto et al. (2017)
Type 2	Degree of target occupancy	The theory suggests that effects may vary in the degree of target occupancy and may be species-dependent. The correlation between target occupancy and effect is crucial for comprehending both inter- and intra-individual variability. Target occupancy information is obtained through in vitro bioassays, tracer displacement in postmortem tissue in vivo, and noninvasive PET/SPECT imaging.	de Witte et al. (2016) Wong et al. (2018)
Type 3	Quantification of the target site activation	In vitro, bioassays provide insights into receptor activation in both animals and humans. Quantitative EEG and fMRI are techniques used to obtain specific receptor activation data in preclinical and clinical in vivo conditions.	Greonendal et al. (2008) Clement et al. (2018)
Type 4	Physiological measures	Physiological measures should be taken within the entire biological system, as they are frequently influenced by homeostatic feedback mechanisms. Measures can be taken on pituitary hormones, which are crucial for communication between the central nervous system and the peripheral nervous system. Quantitative EEG, PET scanning, and functional MRI techniques are highly beneficial for physiological measurements.	Brink et al. (2017) Stevens et al. (2017)
Type 5	Disease processes	This involves the study of disease processes, which are particularly beneficial in clinical conditions.	Erdo et al (2017) Muller et al. (2017)
Type 6	Clinical endpoints	Clinical endpoints refer to the occurrence of a disease, symptom, sign, or laboratory abnormality that correlates with target outcomes.	Holford et al. (2008)

9. Other methods for drug discovery and development

The one-drug, one-target paradigm is one of the factors contributing to the decline in the number of novel medications, and since complicated diseases involve several targets, it makes sense to control them concurrently. This can be accomplished with multiple agents or with just one, but the latter presents difficulties from the standpoint of medicinal chemistry. Nonetheless, this strategy has shown some promise in the search for novel Alzheimer's disease medications (Zhang, 2005). Repurposing, or repositioning, already-existing medications for new uses, is an additional alternate strategy. Thalidime, initially a sedative, has since been approved for leprosy and multiple myeloma, saving time and money by avoiding Phase 1 trials and preclinical safety (Nishimura et al., 2017). Another cutting-edge strategy for drug development is the allostery modulation of drug targets, in which medications

bind at biological target binding sites that are different from active sites. One advantage of this method is that even though multiple proteins may share active sites, Because the allosteric sites may be distinct, selective targeting is possible, leading to fewer or target-specific side effects. BQCA, a positive allosteric modulator of the M1 muscarinic receptor, has shown promise in animal models of schizophrenia (Grover, 2013). Natural products have proven to be the most valuable sources of small molecules for drug development and disease therapy; yet, to increase their physicochemical qualities and produce derivatives, chemical changes are necessary, and these might be difficult to achieve. New strategies are being developed, though, to get past the obstacles and fully realize their potential for creating ground-breaking medications (Robles et al., 2014). The pharmaceutical industry is also taking chances in the search and development of biologics, or drugs derived from biological sources, which could one day produce blockbusters. they include growth factors, polypeptides, hormones, interferons, interleukins, and monoclonal antibodies. Recombinant DNA technology is needed to produce them, as well as vaccinations. They function by aiming for a protein target or a genotype. However, because they are mostly proteins, they can be immunogenic, and they are also highly expensive and difficult to make. Patients who do not respond to traditional therapy or for whom there are no available treatments are typically the target patients (Morrow et al., 2004). To boost creativity in early drug discovery research, crowdsourcing—a partnership between the pharmaceutical business and academia—is being actively explored typically, this is done through the use of the internet. The goal is to raise R&D productivity (Lessl et al., 2011). A new concept in drug development called "network pharmacology" seeks to identify the set of proteins most important to the pathophysiology of disease by exposing synergistic interactions between different medications delivered in combination. Consequently, the objective is to determine the chemicals that attack certain proteins (Hopkins et al., 2008). It is unclear whether these tactics would provide the intended outcomes. The basis and the path ahead for supporting innovation would be science and the long-term strategy. It's crucial to obtain the appropriate attrition at the appropriate periods and search for low medicines' high payout and danger. Microdosing has been a useful strategy in clinical drug development that has helped to boost R&D productivity. Here, the parent drug's or its metabolite's exploratory pharmacokinetics are investigated in people after a sub-pharmacologically active dose is given. Regulatory bodies approve the conduct of this phase, also known as Phase 0, without requiring a full preclinical safety bundle. Compounds with subpar pharmacokinetics are not developed any further. Clinical development is the costliest stage of drug development. It has been suggested that instead of taking the traditional approach based on distinct phases, we should adopt an integrative perspective in which adaptive design tools are used to maximize knowledge accumulation and increase flexibility, potentially leading to the desired outcome (Orloff et al., 2011). Before a new medication can be found on the pharmacy shelf, it will often take ten to fifteen years and more than US$2 billion. New technologies like artificial intelligence and ultra-high-throughput drug screening are accelerating and reducing the cost of early drug development, replacing natural products as the primary source of new drug entities. Berdigaliyev et al. (2020) cellular proteins mediate various organism functions, and lead compounds can modulate target proteins' functions, improving efficacy, and selectivity, and reducing side effects through ligand-receptor interaction knowledge. Computer-aided drug design (CADD) is a cost-effective, rational drug design technology that compares predicted and actual drug activity, enabling iterative improvements in compound properties. CADD-based drug design methods include ligand-based and structure-based approaches, each utilizing different approaches to create compounds that interact with protein structures. Different design methodologies can be used depending on whether the structure of the receptor and its interaction with the ligand are known. Once lead compounds are produced, their potential as potential drugs can be evaluated using the rule of five. The metrics of various drug design methodologies can be estimated using several quality validation techniques, including the efficiency of the hit test, Fisher's cross-validation analysis, and cost function analysis, Hung et al. (2014) virtual screening has evolved from simple similarity searching to a sophisticated application for data mining and machine learning techniques, requiring a large training set for robust decision rules. The amount of chemical and biological data in the public domain is growing at an exponential rate, which has led to a massive effort to develop, evaluate, and use novel learning approaches. This study explores machine learning methods in ligand-based visual sensing (LBVS), analyzing recent research, evaluating advancements and highlighting room for improvement (Lavecchia, 2015). Network-based approaches for drug discovery and development in Fig.2 combining genomes, proteomics, metabolomics, and computational systems biology, are recommended for maximum efficacy and minimal adverse effects (Harrold et al., 2013).



Fig. 2. Applications of imaging in the process of discovering and developing drugs

10. Mechanistic PK/PD models: Converting drug-target kinetics into drug-activity predictions

Models of PK/PD interactions predict the time courses of effects after dose delivery. To fully utilize the insights gained from a comprehensive analysis of binding kinetics, we have developed PK/PD models that integrate drug-target kinetics into estimates of pharmacological activity (Walkup et al., 2015; Daryaee et al., 2016; Daryaee et al., 2017). This means that in conventional PK/PD models, the Hill receptor binding equation is replaced by the entire kinetic scheme that determines the drug binding response coordinate. Thus, both the thermodynamics and the kinetics of drug binding can be used to forecast target engagement as a function of time and drug concentration. The Hill receptor equation assumes immediate equilibrium between target and drug but may underestimate target engagement when medication has a longer residence time than drug clearance rate. In an animal model of infection, the in vivo action of a paLpxC inhibitor and inhibitors of saFabI were correctly predicted using the PK/PD model. PK/PD models predict medication effect duration, incorporating drug-target interactions into activity estimates. Progress in mechanistic models uses preclinical data for drug action in concentration-effect systems. There are several anticipated benefits that these mechanistic models will have over these approaches. An accurate image of drug action and target engagement in the non-equilibrium human body environment can be obtained by employing the entire kinetic scheme explicitly for drug binding, which allows for the computation of time-dependent changes in target occupancy utilizing drug PK and drug–target interaction kinetics. The mechanistic PK/PD models generate target susceptibility functions, providing insight into a target's sensitivity to drug engagement, similar to target occupancy and effect. Modeling variables like target turnover rate and susceptibility provide crucial information on the PK profile needed for desired pharmacological effect and kinetic selectivity in medication development (Daryaee et al., 2019). Clinical trials often fail due to poor therapeutic index or limited target engagement, but reducing exposure can minimize off-target effects without compromising the desired pharmacodynamic response in kinetic selectivity drugs. A mechanistic model of Parkinson's disease incorporates drug-target kinetic parameters, including the creation and disintegration on- and off-rates of the complex, to better integrate drug-target residence duration into drug discovery. The study suggests that longer residence times in drug-target interactions can improve predictions of medication efficacy and safety, potentially leading to permanent pharmacological activity, while shorter residence times may be beneficial for negative targets. Consequently, incorporating residence time into the first phases of drug development and discovery has produced several clinical candidates that exhibit encouraging in vivo efficacy and safety characteristics. Thus, residence time research provides insights that help translate in vitro potency to in vivo safety and efficacy. The process of finding new pharmaceuticals and forming safer, more potent medications would benefit greatly from additional studies and developments in the measurement and optimization of residence duration (Liu et al., 2013).

11. Chemical tools to assess in vivo target susceptibility and target engagement

Using data from in vitro cell washout studies, the PK/PD model discussed earlier optimizes the parameters required to predict in vivo drug activity.

The study suggests that direct measurement of in vivo target engagement could enhance the strategy for determining drug binding and efficacy, as demonstrated in the study of CC-292. Active site-directed covalent probes can be formed in systems that use covalent inhibition, like tyrosine kinases with conserved Cys at their active sites (Blair et al., 2007; Evans et al., 2013). Nonreceptor tyrosine kinase Btk is a potential target for the therapy of B-cell malignancies, various diseases caused by B cell dysregulation and autoimmune disorders such as lupus and rheumatoid arthritis (Katewa et al., 2017; Paolo et al., 2013; Martinez-Gamboa et al., 2006; Wang et al., 2017; Robak et al., 2012). An acrylamide electrophile was found in CC-292 and medications like ibrutinib (Honigberg et al., 2010) combined with a conserved Cys (481) in the Btk active site. A fluorescent probe was developed to measure Btk engagement by CC-292 in Ramos cells and B lymphocytes from rats. The drug's binding to Btk was measured and its kinetic parameters were calculated using plasma concentration, eliminating the need for cell membrane estimation. The cellular Btk to pure Btk Ki values were 80, indicating a concentration of CC-292 80 times lower than media or plasma. A PK/PD model was used to predict Btk's effectiveness in a rat model of collagen-induced arthritis. The rat CIA model shows Btk susceptibility function suggests occupancy levels above 90% are necessary for maximal efficacy, while engagement below 50% has no positive impact. CC-292 is predicted to be effective. We developed a fluorescent probe based on CC-292 to assess the level of Btk engagement by CC-292 in both cell culture (Ramos cells) and B lymphocytes isolated from rats administered CC-292 dosages. To calculate the initial values for PK/PD modeling, the rate of Btk turnover was estimated by measuring the binding of CC-292 to Btk in Ramos cells under equilibrium conditions and then after CC-292 was washed off. Moreover, the necessity to determine the drug concentration across the cell membrane was eliminated since the kinetic parameters for CC-292's inhibition of Btk were calculated using the extracellular concentration of CC-292 in plasma (free fraction).

12. Conclusions

The field of study focuses on examining pharmacokinetics and pharmacodynamics in therapeutic development, which is a dynamic and constantly evolving area of study. Researchers have made significant progress in understanding drug behavior within biological systems by integrating advanced technologies and interdisciplinary approaches. These studies provide valuable insights into drug efficacy and safety, laying the groundwork for the formation of innovative therapeutic interventions. The field of drug discovery and development is poised for a promising future due to advancements in pharmacokinetics and pharmacodynamics research. Artificial intelligence and machine learning are set to revolutionize drug design, enabling swift identification of promising candidates and optimizing therapeutic outcomes. The integration of omics technologies with pharmacokinetic and pharmacodynamic studies has the potential to revolutionize personalized medicine, allowing personalized treatments for each individual patient. The advancement of innovative drug delivery systems and targeted approaches will significantly influence drug development, enhancing efficacy and minimizing adverse effects. The development of drugs requires a multifaceted approach that involves collaboration between academia, industry, and regulatory agencies to translate basic research into clinically beneficial interventions. Pharmacokinetics and pharmacodynamics, using advanced technology and interdisciplinary collaboration, have the potential to revolutionize drug discovery, development, patient outcomes, and healthcare. Given their ability to shed light on drug distribution, metabolism, excretion, and absorption, pharmacokinetics and pharmacodynamics play a critical role in drug discovery and development. Innovative methodologies and interdisciplinary collaborations have made significant progress in understanding drug behavior, deepening drug efficacy and safety. Advancements in pharmacokinetics and pharmacodynamics, computational modeling, artificial intelligence, and high-throughput screening are set to revolutionize drug design, while nanotechnology and targeted delivery offer opportunities. Pharmacokinetics and pharmacodynamics have the potential to revolutionize drug development, improve patient outcomes, and promote global health through innovative collaborations.

References

1. Alampanos, V., Samanidou, V., & Papadoyannis, I. (2019). Trends in Sample Preparation for the HPLC Determination of Penicillins in Biofluids. Journal of Applied Bioanalysis, 5(1), 9–17.
2. Agoram, B. M., Martin, S. W., Van der Graaf, P. H. 2007. The role of mechanism-based pharmacokinetic–pharmacodynamic (PK–PD) modeling in translational research of biologics. Drug Discovery Today, 12(23-24), 1018-1024.
3. Andersson, T. B., Bredberg, E., Ericsson, H., Sjöberg, H. 2004. An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9

substrates. Drug Metabolism and Disposition, 32(7), 715-721.
4. Ashford, J. W., Schmitt, F. A. 2001. Modeling the time-course of Alzheimer's dementia. Current Psychiatry Reports, 3(1), 20-28.
5. Azad, A. K., Praveen, M., & Sulaiman, W. M. A. B. W. (2024). Assessment of Anticancer Properties of Plumbago zeylanica. Harnessing Medicinal Plants in Cancer Prevention and Treatment, 91–121. https://doi.org/10.4018/979-8-3693-1646-7.ch004
6. Beier, H., Garrido, M. J., Christoph, T., et al. 2008. Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antinociceptive response in the presence of competitive antagonism. Pharmaceutical research, 25(8), 1789–1797. https://doi.org/10.1007/s11095-007-9489-8.
7. Bender, G., Gosset, J., Florian, J., et al. 2009. Population pharmacokinetic model of the pregabalin-sildenafil interaction in rats: application of simulation to preclinical PK-PD study design. Pharmaceutical research, 26(10), 2259–2269. https://doi.org/10.1007/s11095-009-9942-y.
8. Berdigaliyev, N., Aljofan, M. 2020. An overview of drug discovery and development. Future Medicinal Chemistry, 12(10), 939–947.
9. Bergen, A. A., Kaing, S., ten Brink, J. B., et al. 2015. Gene expression and functional annotation of human choroid plexus epithelium failure in Alzheimer's disease. BMC genomics, 16, 956. https://doi.org/10.1186/s12864-015-2159-zBettler,
10. Bhavnani, S. M., Krause, K. M., Ambrose, P. G. 2020. A broken antibiotic market: Review of strategies to incentivize drug development. Open Forum Infectious Diseases, 7(7), ofaa083.
11. Blair, J. A., Rauh, D., Kung, C., et al. 2007. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nature chemical biology, 3(4), 229–238. https://doi.org/10.1038/nchembio866
12. Block, M. 2015. Physiologically based pharmacokinetic and pharmacodynamic modeling in cancer drug development: status, potential and gaps. Expert Opinion on Drug Metabolism & Toxicology, 11(5), 743-756.
13. Boxenbaum, H. 1982. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics, 10, 201-227.
14. Burt, T., Young, G., Lee, W., et al. 2020. Phase 0/microdosing approaches: time for mainstream application in drug develodevelopment? e reviews. Drug discovery, 19(11), 801–818. https://doi.org/10.1038/s41573-020-0080-x
15. Calipari, E. S., Ferris, M. J. 2013. Amphetamine mechanisms and actions at the dopamine terminal revisited. Journal of Neuroscience, 33(21), 8923-8925.
16. Chiba, M., Ishii, Y., Sugiyama, Y. 2009. Prediction of hepatic clearance in humans from in vitro data for successful drug development. The AAPS Journal, 11, 262-276.
17. Clement, P., Mutsaerts, H. J., Václavů, L., et al. 2018. Variability of physiological brain perfusion in healthy subjects - A systematic review of modifiers. International Society of Cerebral Blood Flow and Metabolism, 38(9), 1418–1437. https://doi.org/10.1177/0271678X17702156
18. Danhof, M., Alvan, G., Dahl, S. G., et al. 2005. Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers. Pharmaceutical research, 22(9), 1432–1437. https://doi.org/10.1007/s11095-005-5882-3
19. Danhof, M., de Jongh, J., De Lange, E. C., et al. 2007. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annual Review of Pharmacology and Toxicology, 47, 357-400.
20. Danhof, M., De Lange, E. C., Della Pasqua, O. E., et al. 2008. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends in Pharmacological Sciences, 29(4), 186-191.
21. Daryaee, F., Tonge, P. J. 2017. A quantitative mechanistic PK/PD model directly connects Btk target engagement and in vivo efficacy. Chemical Science, 8(5), 3434–3443.
22. Daryaee, F., Tonge, P. J. 2019. Pharmacokinetic–pharmacodynamic models that incorporate drug–target binding kinetics. Current Opinion in Chemical Biology, 50, 120–127.
23. Daryaee, F., Chang, A., Schiebel, J., et al. 2016. Correlating Drug-Target Kinetics and In vivo Pharmacodynamics: Long Residence Time Inhibitors of the FabI Enoyl-ACP Reductase. Chemical science, 7(9), 5945–5954. https://doi.org/10.1039/C6SC01000H.
24. de Lange, E. C. 2013. The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects. Fluids and Barriers of the CNS, 10, 1-16.
25. de Lange, E. C. 2015. PBPK Modeling Approach for Predictions of Human CNS Drug Brain Distribution. Blood-Brain Barrier in Drug

Discovery, 296–323. https://doi.org/10.1002/9781118788523.ch14
26. de Lange, E. C., Ravenstijn, P. G., Groenendaal, D., van Steeg, T. J. 2005. Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling. The AAPS Journal, 7, E532-E543.
27. de Witte, W. E., Danhof, M., van der Graaf, P. H., de Lange, E. C. 2016. In vivo target residence time and kinetic selectivity: The association rate constant as determinant. Trends in Pharmacological Sciences, 37(10), 831-842.
28. de Witte, W. E., Wong, Y. C., Nederpelt, I., et al. 2016. Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients. Expert opinion on drug discovery, 11(1), 45–63. https://doi.org/10.1517/17460441.2016.1100163
29. Di Paolo, J. A., Huang, T., Balazs, M., et al. 2011. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nature chemical biology, 7(1), 41–50. https://doi.org/10.1038/nchembio.481
30. Di, L., Feng, B., Goosen, T. C., et al .2013. A perspective on the prediction of drug pharmacokinetics and disposition in drug research and development. Drug metabolism and disposition: the biological fate of chemicals, 41(12), 1975–1993. https://doi.org/10.1124/dmd.113.054031
31. Dokoumetzidis, A., Iliadis, A., Macheras, P. 2002. Nonlinear dynamics in clinical pharmacology: the paradigm of cortisol secretion and suppression. British Journal of Clinical Pharmacology, 54(1), 21.
32. Dong, J. Q., Chen, B., Gibbs, M. A., et al. 2008. Applications of computer-aided pharmacokinetic and pharmacodynamic methods from drug discovery through registration. Current Computer-Aided Drug Design, 4 (1), 54-66.
33. Drexler, D. M., McNaney, C. A., Wang, Y., Huang, X., & Reily, M. D. (2018). The utility of qNMR to improve accuracy and precision of LC-MS bioanalysis. Journal of Applied Bioanalysis, 4(1), 26–31.
34. Drusano, G. L. (2004). Antimicrobial pharmacodynamics: Critical interactions of 'bug and drug'. Nature Reviews Microbiology, 2(4), 289-300.
35. Erdő, F., Denes, L., de Lange, E. 2017. Age-associated physiological and pathological changes at the blood–brain barrier: A review. Journal of Cerebral Blood Flow & Metabolism, 37(1), 4-24.
36. Evans, E. K., Tester, R., Aslanian, S., et al. 2013. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. The Journal of pharmacology and experimental therapeutics, 346(2), 219–228. https://doi.org/10.1124/jpet.113.203489.
37. Fakler, B. 2017. Ionotropic AMPA-type glutamate and metabotropic GABAB receptors: Determining cellular physiology by proteomes. Current Opinion in Neurobiology, 45, 16-23.
38. Faria, M., Ismaiel, O., Waltrip, J., Mariannino, T., Yuan, M., Mylott, W., Roongta, V., Shen, J., & Kadiya, P. (2020). LC-MS/MS Method for the Quantitative Determination of Tanespimycin and its Active Metabolite in Human Plasma: Method Validation and Overcoming an Insidious APCI Source Phenomenon. Journal of Applied Bioanalysis, 6(3), 145–163.
39. Finnema, S. J., Scheinin, M., Shahid, M., et al. 2015. Application of cross-species PET imaging to assess neurotransmitter release in brain. Psychopharmacology, 232(21-22), 4129–4157. https://doi.org/10.1007/s00213-015-3938-6.
40. Fridén, M., Winiwarter, S., Jerndal, G., et al. 2009. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. Journal of medicinal chemistry, 52(20), 6233–6243. https://doi.org/10.1021/jm901036q.
41. Gabrielsson, J., Dolgos, H., Gillberg, P.-G., et al. 2009. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations. Drug Discovery Today, 14(7-8), 358-372.
42. Gabrielsson, J., Hjorth, S. 2016. Pattern recognition in pharmacodynamic data analysis. The AAPS Journal, 18, 64-91.
43. Gabrielsson, J., Peletier, L. A. 2014. Dose–response–time data analysis involving nonlinear dynamics, feedback and delay. European Journal of Pharmaceutical Sciences, 59, 36-48.
44. Gabrielsson, J., Peletier, L. A., Hjorth, S. 2018. In vivo potency revisited–keep the target in sight. Pharmacology & Therapeutics, 184, 177-188.
45. Gabrielsson, J., Weiner, D. 2001. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications.
46. Gao, W., Jusko, W. J. 2012. Target-mediated pharmacokinetic and pharmacodynamic model

of exendin-4 in rats, monkeys, and humans. Drug Metabolism and Disposition, 40(5), 990-997.
47. Gaugler, S., Rykl, J., Grill, M., & Cebolla, V. L. (2018). Fully automated drug screening of dried blood spots using online LC-MS/MS analysis. Journal of Applied Bioanalysis, 4(1), 7–15.
48. Gibiansky, L., Gibiansky, E. 2009. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic–pharmacodynamic modeling of biologics. Expert Opinion on Drug Metabolism & Toxicology, 5(7), 803-812.
49. Groenendaal, D., Freijer, J., Rosier, A., et al. 2008. Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 34(2-3), 149–163. https://doi.org/10.1016/j.ejps.2008.03.003.
50. Groeneveld, G. J., Hay, J. L.,Van Gerven, J. M. 2016. Measuring blood–brain barrier penetration using the NeuroCart, a CNS test battery. Drug Discovery Today: Technologies, 20, 27-34.
51. Grover, A. K. 2013. Use of allosteric targets in the discovery of safer drugs. Medical Principles and Practice, 22(5), 418–426.
52. Harrold, J., Ramanathan, M., Mager, D. 2013. Network-based approaches in drug discovery and early development. Clinical Pharmacology & Therapeutics, 94(6), 651–658.
53. Holford, N., Nutt, J. G. 2008. Disease progression, drug action and Parkinson's disease: Why time cannot be ignored. European Journal of Clinical Pharmacology, 64, 207-216.
54. Honigberg, L. A., Smith, A. M., Sirisawad, M., et al. 2010. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proceedings of the National Academy of Sciences of the United States of America, 107(29), 13075–13080. https://doi.org/10.1073/pnas.1004594107
55. Hopkins, A. L. 2008. Network pharmacology: The next paradigm in drug discovery. Nature Chemical Biology, 4(11), 682–690.
56. Houston, J. B., Galetin, A. 2008. Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Current Drug Metabolism, 9(9), 940-951.
57. Hung, C. L., Chen, C. C. 2014. Computational approaches for drug discovery. Drug Development Research, 75(6), 412–418.
58. Huntley, M. A., Bien-Ly, N., Daneman, R., Watts, R. J. 2014. Dissecting gene expression at the blood-brain barrier. Frontiers in Neuroscience, 8, 355.
59. Ito, K., Houston, J. B. 2004. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharmaceutical Research, 21, 785-792.
60. Iwatsubo, T., Hirota, N., Ooie, T., et al. 1997. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacology & therapeutics, 73(2), 147–171. https://doi.org/10.1016/s0163-7258(96)00184-2
61. Jonsson, E. N., Macintyre, F., James, I., et al. 2005. Bridging the pharmacokinetics and pharmacodynamics of UK-279,276 across healthy volunteers and stroke patients using a mechanistically based model for target-mediated disposition. Pharmaceutical research, 22(8), 1236–1246. https://doi.org/10.1007/s11095-005-5264-x
62. Jumbe, N. L., Xin, Y., Leipold, D. D., et al. 2010. Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. Journal of pharmacokinetics and pharmacodynamics, 37(3), 221–242. https://doi.org/10.1007/s10928-010-9156-2
63. Kaddurah-Daouk, R., Kristal, B. S., Weinshilboum, R. M. 2008. Metabolomics: a global biochemical approach to drug response and disease. Annual Review of Pharmacology and Toxicology, 48, 653-683.
64. Katewa, A., Wang, Y., Hackney, J. A., et al. 2017. Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis. JCI insight, 2(7), e90111. https://doi.org/10.1172/jci.insight.90111
65. Kraus, V. B. 2018. Biomarkers as drug development tools: Discovery, validation, qualification and use. Nature Reviews Rheumatology, 14(6), 354-362.
66. Kummar, S., Kinders, R., Rubinstein, L., et al. 2007. Compressing drug development timelines in oncology using phase '0' trials. Nature reviews. Cancer, 7(2), 131–139. https://doi.org/10.1038/nrc2066.
67. Lalonde, R. L., Kowalski, K. G., Hutmacher, M. M., et al. 2007. Model-based drug development. Clinical pharmacology and therapeutics, 82(1), 21–32. https://doi.org/10.1038/sj.clpt.6100235
68. Lappin, G., Noveck, R., Burt, T. 2013. Microdosing and drug development: past, present and future. Expert Opinion on Drug Metabolism & Toxicology, 9(7), 817-834.
69. Lavecchia, A. 2015. Machine-learning approaches in drug discovery: Methods and

applications. Drug Discovery Today, 20(3), 318–331.
70. Lessl, M., Bryans, J. S., Richards, D., Asadullah, K. 2011. Crowd sourcing in drug discovery. Nature Reviews Drug Discovery, 10(4), 241–242.
71. Liu, H., Zhang, H., IJzerman, A. P., Guo, D. 2023. The translational value of ligand-receptor binding kinetics in drug discovery. British journal of pharmacology, 10.1111/bph.16241. Advance online publication. https://doi.org/10.1111/bph.16241
72. Liu, S., Cai, W., Liu, S., et al. 2015. Multimodal neuroimaging computing: a review of the applications in neuropsychiatric disorders. Brain informatics, 2(3), 167–180. https://doi.org/10.1007/s40708-015-0019-x
73. Lobo, E. D., Hansen, R. J., Balthasar, J. P. 2004. Antibody pharmacokinetics and pharmacodynamics. Journal of Pharmaceutical Sciences, 93(11), 2645-2668.
74. LoRusso, P. M. 2009. Phase 0 clinical trials: an answer to drug development stagnation? Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 27(16), 2586-2588.
75. Marchetti, S., Schellens, J. 2007. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. British Journal of Cancer, 97(5), 577-581.
76. Margineanu, D. G. 2016. Neuropharmacology beyond reductionism–a likely prospect. Biosystems, 141, 1-9.
77. Martinez-Gamboa, L., Brezinschek, H. P., Burmester, G. R., Dörner, T. 2006. Immunopathologic role of B lymphocytes in rheumatoid arthritis: rationale of B cell-directed therapy. Autoimmunity reviews, 5(7), 437–442. https://doi.org/10.1016/j.autrev.2006.02.004.
78. Mayer, B., Heinzel, A., Lukas, A., Perco, P. 2017. Predictive biomarkers for linking disease pathology and drug effect. Current Pharmaceutical Design, 23(1), 29-54.
79. Meibohm, B., Derendorf, H. 2004. Pharmacokinetics and pharmacodynamics of biotech drugs. In Pharmaceutical biotechnology: Drug discovery and clinical applications (pp. 145-172).
80. Miller, R., Ewy, W., Corrigan, B. W., et al. 2005. How Modeling and Simulation Have Enhanced Decision Making in New Drug Development. Journal of Pharmacokinetics and Pharmacodynamics, 32(2), 185–197. https://doi.org/10.1007/s10928-005-0074-7
81. Morgan, P., Van Der Graaf, P. H., Arrowsmith, J., et al. 2012. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug discovery today, 17(9-10), 419–424. https://doi.org/10.1016/j.drudis.2011.12.020.
82. Morrow, T., Felcone, L. H. 2004. Defining the difference: What makes biologics unique. Biotechnology Healthcare, 1(4), 24.
83. Müller, U. C., Deller, T., Korte, M. 2017. Not just amyloid: Physiological functions of the amyloid precursor protein family. Nature Reviews Neuroscience, 18(5), 281-298.
84. Nishimura, Y., Tagawa, M., Ito, H., Tsuruma, K., & Hara, H. (2017). Overcoming Obstacles to Drug Repositioning in Japan. Frontiers in pharmacology, 8, 729. https://doi.org/10.3389/fphar.2017.00729
85. Obach, R. S., Baxter, J. G., Liston, T. E., et al. 1997. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. The Journal of pharmacology and experimental therapeutics, 283(1), 46–58.
86. Orloff, J. J., Stanski, D. 2011. Innovative approaches to clinical development and trial design. Annali dell'Istituto Superiore di Sanità, 47, 8–13.
87. Overgaard, R. V., Holford, N., Rytved, K. A., Madsen, H. 2007. Pkpd model of interleukin-21 effects on thermoregulation in monkeys—application and evaluation of stochastic differential equations. Pharmaceutical Research, 24, 298-309.
88. Praveen, M. (2024). Characterizing the West Nile Virus's polyprotein from nucleotide sequence to protein structure - Computational tools. J Taibah Univ Med Sci. 19(2):338-350. doi: 10.1016/j.jtumed.2024.01.001.
89. Praveen, M. (2024). Multi-epitope-based vaccine designing against Junín virus glycoprotein: immunoinformatics approach. Futur J Pharm Sci 10, 29. 12-24.
90. Praveen, M., Morales-Bayuelo, A. (2023). Drug Designing against VP4, VP7 and NSP4 of Rotavirus Proteins – Insilico studies, Mor. J. Chem., 14(6), 729-741.
91. Praveen, M., Ullah, I., Buendia, R., Khan, I. A., Sayed, M. G., Kabir, R., Bhat, M. A., Yaseen, M. (2024). Exploring Potentilla nepalensis Phytoconstituents: Integrated Strategies of Network Pharmacology, Molecular Docking, Dynamic Simulations, and MMGBSA Analysis for Cancer Therapeutic Targets Discovery. Pharmaceuticals (Basel). 17(1):134. doi: 10.3390/ph17010134.
92. Rajman, I. 2008. PK/PD modelling and simulations: utility in drug development. Drug Discovery Today, 13(7-8), 341-346.

93. Robak, T., Robak, E. 2012. Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders. Expert opinion on investigational drugs, 21(7), 921–947. https://doi.org/10.1517/13543784.2012.685650
94. Robles, O., Romo, D. 2014. Chemo- and site-selective derivatizations of natural products enabling biological studies. Natural Product Reports, 31(3), 318–334.
95. Rohatagi, S., Carrothers, T. J., Kuwabara-Wagg, J., Khariton, T. 2009. Is a thorough QTc study necessary? The role of modeling and simulation in evaluating the QTc prolongation potential of drugs. The Journal of Clinical Pharmacology, 49(11), 1284-1296.
96. Sahu, P., Pinkalwar, N., Dubey, R. D., et al. 2011. Biomarkers: An emerging tool for diagnosis of a disease and drug development. Asian Journal of Research in Pharmaceutical Science, 1(1), 9-16.
97. Sarawek, S., Li, L., Yu, X., et al. 2009. Examination of the Utility of the High Throughput In Vitro Metabolic Stability Assay to Estimate In Vivo Clearance in the Mouse. The Open Drug Metabolism Journal, 3, 31–42. https://doi.org/10.2174/1874073100903010031
98. Sawada, Y., Kawai, R., McManaway, M., et al. 1991. Kinetic analysis of transport and opioid receptor binding of [3H] (-)-cyclofoxy in rat brain in vivo: implications for human studies. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 11(2), 183–203. https://doi.org/10.1038/jcbfm.1991.51.
99. Sheiner, L., Steimer, J.-L. 2000. Pharmacokinetic/pharmacodynamic modeling in drug development. Annual Review of Pharmacology and Toxicology, 40(1), 67-95.
100. Simeoni, M., Magni, P., Cammia, C., et al. 2004. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer research, 64(3), 1094–1101. https://doi.org/10.1158/0008-5472.can-03-2524.
101. Slifstein, M., Abi-Dargham, A. 2017. Recent developments in molecular brain imaging of neuropsychiatric disorders. In Seminars in Nuclear Medicine, 47(1), 54-63.
102. Soars, M. G., Webborn, P. J., Riley, R. J. 2009. Impact of hepatic uptake transporters on pharmacokinetics and drug− drug interactions: use of assays and models for decision making in the pharmaceutical industry. Molecular Pharmaceutics, 6(6), 1662-1677.
103. Stevens, J., Ploeger, B. A., Hammarlund-Udenaes, M., et al. 2012. Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans. Journal of pharmacokinetics and pharmacodynamics, 39(5), 463–477. https://doi.org/10.1007/s10928-012-9262-4
104. Tabrizi, M. A., Tseng, C.-M. L., Roskos, L. K. 2006. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discovery Today, 11(1-2), 81-88.
105. Tardiff, D. F., Lindquist, S. 2013. Phenotypic screens for compounds that target the cellular pathologies underlying Parkinson's disease. Drug Discovery Today: Technologies, 10(1), e121-e128.
106. Terstappen, G. C., Schlüpen, C., Raggiaschi, R., Gaviraghi, G. 2007. Target deconvolution strategies in drug discovery. Nature Reviews Drug Discovery, 6(11), 891-903.
107. Tewari, T., Mukherjee, S. 2010. Microdosing: concept, application and relevance. Perspectives in Clinical Research, 1(2), 61.
108. Thanga Mariappan, T., Mandlekar, S., Marathe, P. 2013. Insight into Tissue Unbound Concentration: Utility in Drug Discovery and Development. Current Drug Metabolism, 14(3), 324-340.
109. Tuntland, T., Ethell, B., Kosaka, T., et al. 2014. Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research. Frontiers in pharmacology, 5, 174. https://doi.org/10.3389/fphar.2014.00174
110. Uchida, Y., Tachikawa, M., Obuchi, W., et al. 2013. A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood-brain barrier in ddY, FVB, and C57BL/6J mice. Fluids and barriers of the CNS, 10(1), 21. https://doi.org/10.1186/2045-8118-10-21
111. Uchida, Y., Zhang, Z., Tachikawa, M., Terasaki, T. 2015. Quantitative targeted absolute proteomics of rat blood–cerebrospinal fluid barrier transporters: Comparison with a human specimen. Journal of Neurochemistry, 134(6), 1104-1115.
112. Uchizono, J. A., Lane, J. R. 2007. Empirical pharmacokinetic/pharmacodynamic models. In Pharmacometrics: The Science of Quantitative Pharmacology (pp. 529-545).

113. van den Anker, J., Reed, M. D., Allegaert, K., Kearns, G. L. 2018. Developmental changes in pharmacokinetics and pharmacodynamics. The Journal of Clinical Pharmacology, 58, S10-S25.
114. van den Brink, W. J., Elassaiss-Schaap, J., Gonzalez-Amoros, B., et al. 2017. Multivariate pharmacokinetic/pharmacodynamic (PKPD) analysis with metabolomics shows multiple effects of remoxipride in rats. European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences, 109, 431–440. https://doi.org/10.1016/j.ejps.2017.08.031
115. van den Brink, W. J., Wong, Y. C., Gülave, B., et al. 2017. Revealing the neuroendocrine response after remoxipride treatment using multi-biomarker discovery and quantifying it by PK/PD modeling. The AAPS Journal, 19, 274-285.
116. van der Greef, J., McBurney, R. N. 2005. Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nature Reviews Drug Discovery, 4(12), 961-967.
117. Van Rossum, J., Van Koppen, A. T. J. 1968. Kinetics of psycho-motor stimulant drug action. European Journal of Pharmacology, 2(5), 405-408.
118. Walkup, G. K., You, Z., Ross, P. L., et al. 2015. Translating slow-binding inhibition kinetics into cellular and in vivo effects. Nature chemical biology, 11(6), 416–423. https://doi.org/10.1038/nchembio.1796
119. Wang, S., Guo, P., Wang, X., et al.2008. Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models. Molecular Cancer Therapeutics, 7(2), 407-417.
120. Wang, X., Barbosa, J., Blomgren, P., et al. 2017. Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties. ACS medicinal chemistry letters, 8(6), 608–613. https://doi.org/10.1021/acsmedchemlett.7b00103
121. Wang, Y., Welty, D. R. 1996. The simultaneous estimation of the influx and efflux blood-brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach. Pharmaceutical Research, 13, 398-403.
122. Westerhout, J., Ploeger, B., Smeets, J., et al. 2012. Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats. The AAPS journal, 14(3), 543–553. https://doi.org/10.1208/s12248-012-9366-1
123. Westerhout, J., Van den Berg, D.-J., Hartman, R., et al. 2014. Prediction of methotrexate CNS distribution in different species–Influence of disease conditions. European Journal of Pharmaceutical Sciences, 57, 11-24.
124. Whiteside, G. T., Kennedy, J. D. 2011. Consideration of pharmacokinetic pharmacodynamic relationships in the discovery of new pain drugs.
125. Wong, Y. C., Ilkova, T., van Wijk, R. C., et al. 2018. Development of a population pharmacokinetic model to predict brain distribution and dopamine D2 receptor occupancy of raclopride in non-anesthetized rat. European Journal of Pharmaceutical Sciences, 111, 514-525.
126. Yamamoto, Y., Välitalo, P. A., van den Berg, D. J., et al. 2017. A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations. Pharmaceutical research, 34(2), 333–351. https://doi.org/10.1007/s11095-016-2065-3.
127. Yamasaki, Y., Tiran, J., Albisser, A. M. 1984. Modeling glucose disposal in diabetic dogs fed mixed meals. American Journal of Physiology-Endocrinology and Metabolism, 246(1), E52-E61.
128. Yao, Z., DuBois, D. C., Almon, R. R., Jusko, W. J. 2008. Pharmacokinetic/pharmacodynamic modeling of corticosterone suppression and lymphocytopenia by methylprednisolone in rats. Journal of Pharmaceutical Sciences, 97(7), 2820-2832.
129. Yu, R. Z., Lemonidis, K. M., Graham, M. J., et al. 2009. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochemical pharmacology, 77(5), 910–919. https://doi.org/10.1016/j.bcp.2008.11.005.
130. Yu, X. Q., Kramer, J., Moran, L., et al. 2010. Pharmacokinetic/pharmacodynamic modelling of 2-acetyl-4(5)-tetrahydroxybutyl imidazole-induced peripheral lymphocyte sequestration through increasing lymphoid sphingosine 1-phosphate. Xenobiotica; the fate of foreign compounds in biological systems, 40(5), 350–356. https://doi.org/10.3109/00498251003611376
131. Yu, X.-Q., Wilson, A. G. 2010. The role of pharmacokinetic and pharmacokinetic/pharmacodynamic modeling in drug discovery and development. Future Medicinal Chemistry, 2(6), 923-928.
132. Zhang, H.-Y. 2005. One-compound-multiple-targets strategy to combat Alzheimer's disease. FEBS Letters, 579(24), 5260–5264.
133. Zuegge, J., Schneider, G., Coassolo, P., Lavé, T. 2001. Prediction of hepatic metabolic

clearance: comparison and assessment of prediction models. Clinical Pharmacokinetics, 40, 553-563.